Akèy › Maladi fwa steatotik › Missouri
Etid klinik pou Maladi fwa steatotik nan Missouri
14 etid pou Maladi fwa steatotik ap chèche patisipan nan sit nan Missouri.
Vil nan Missouri
Tèks ofisyèl etid la (Anglè)
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, St Louis
- 89bio Clinical Study Site, St Louis
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Oct 5, 2026 · NCT06419374A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- 89bio Clinical Study Site, St Louis
Ap rekriteFaz 3
Laj 18 a 80 · Tout sèks · Mizajou Oct 5, 2026 · NCT06318169A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
- GSK Investigational Site, St Louis
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Sep 30, 2026 · NCT07704892A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
- GSK Investigational Site, St Louis
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Sep 30, 2026 · NCT07701993A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
- Washington University School of Medicine, St Louis
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 25, 2026 · NCT05519475A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- AMR Clinical, Kansas City
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07165028A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Akero Clinical Study Site, Columbia
- Akero Clinical Study Site, Kansas City
- Akero Clinical Study Site, St Louis
- ak 1 plis
Ap rekriteFaz 3
Laj 18 a 80 · Tout sèks · Mizajou Sep 21, 2026 · NCT06528314A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
- GSK Investigational Site, Springfield
- GSK Investigational Site, St Louis
- GSK Investigational Site, St Louis
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Sep 17, 2026 · NCT07221188A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Gastrointestinal Associates, Columbia
- Gateway GI Research, LLC, St Louis
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 9, 2026 · NCT07288138Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity (ATM)
- University of Missouri School of Medicine, Columbia
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 a 70 · Tout sèks · Mizajou Aug 6, 2026 · NCT06571474Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity
- University of Missouri School of Medicine, Columbia
Ap rekriteVolontè an sante akeyi
Laj 18 a 70 · Tout sèks · Mizajou Aug 6, 2026 · NCT06335771A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
- GSK Investigational Site, Kansas City
- GSK Investigational Site, Springfield
- GSK Investigational Site, St Louis
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Jul 27, 2026 · NCT07221227A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
- GSK Investigational Site, Kansas City
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Jul 8, 2026 · NCT06920043Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans
- Harry S. Truman Memorial, Columbia, MO, Columbia
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Feb 19, 2026 · NCT05526144Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.